Lotus Pharmaceuticals, Inc.
LTUS
$0.0053
-$0.0007-11.67%
OTC PK
| 09/30/2011 | 06/30/2011 | 03/31/2011 | 12/31/2010 | 09/30/2010 | |
|---|---|---|---|---|---|
| Revenue | 3.39% | 8.30% | 18.67% | 29.82% | 7.38% |
| Total Other Revenue | -- | -- | -75.00% | -70.43% | -75.21% |
| Total Revenue | 3.39% | 8.30% | 18.28% | 27.65% | 3.79% |
| Cost of Revenue | 46.30% | 29.41% | 28.07% | 31.39% | -1.52% |
| Gross Profit | -32.97% | -9.36% | 10.60% | 24.67% | 8.76% |
| SG&A Expenses | 6.09% | 29.91% | 47.44% | 56.88% | 25.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.83% | 33.08% | 36.44% | 39.76% | 5.65% |
| Operating Income | -66.51% | -40.24% | -15.38% | 5.03% | 0.23% |
| Income Before Tax | -93.03% | -64.13% | -34.86% | -12.83% | 5.02% |
| Income Tax Expenses | -136.66% | -108.94% | -70.17% | -40.25% | 334.86% |
| Earnings from Continuing Operations | -91.59% | -62.84% | -34.07% | -12.22% | 2.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -91.59% | -62.84% | -34.07% | -12.22% | 2.45% |
| EBIT | -66.51% | -40.24% | -15.38% | 5.03% | 0.23% |
| EBITDA | -60.92% | -36.53% | -13.37% | 5.78% | 4.40% |
| EPS Basic | -92.83% | -66.98% | -43.80% | -25.52% | -13.73% |
| Normalized Basic EPS | -66.64% | -42.47% | -20.07% | -2.31% | -3.58% |
| EPS Diluted | -92.70% | -64.64% | -38.37% | -19.66% | -8.30% |
| Normalized Diluted EPS | -65.05% | -38.00% | -11.30% | 7.97% | 3.89% |
| Average Basic Shares Outstanding | 8.53% | 12.69% | 17.16% | 18.41% | 16.89% |
| Average Diluted Shares Outstanding | 3.28% | 4.42% | 5.52% | 6.91% | 8.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |